Literature DB >> 9366672

Botulinum toxin management of essential infantile esotropia in children.

K W McNeer1, M G Tucker, R F Spencer.   

Abstract

BACKGROUND: Infantile esotropia has an onset during early infancy when visual cortical connections are established for binocular fusion and stereopsis. The goal of early treatment is to achieve normal binocular alignment and a favorable sensory outcome.
OBJECTIVE: To determine the long-term effects of the use of botulinum toxin for the management of infantile esotropia in children. PATIENTS: Seventy-six neurologically normal children ranging from 4 to 48 months of age were entered consecutively into the study after being given the initial diagnosis of infantile esotropia with a mean strabismic angle of 33 prism diopters.
INTERVENTIONS: Simultaneous bilateral injections of 2.5 U of botulinum toxin type A were made into the medial rectus muscles under nitrous oxide and ethrane anesthesia. Patients were followed up for 12 to 95 months after the last injection. Forty patients required 1 bilateral injection and 36 patients required multiple bilateral injections to achieve a favorable motor outcome.
RESULTS: Bilateral medial rectus muscle injections of botulinum toxin were effective in reducing the mean preinjection deviation of 33 PD to an average esotropic angle of 2 PD. Binocular alignment (+/- 10 PD) was achieved in 68 patients (89%). Boys required significantly fewer injections than did girls. The secondary incidence of overacting inferior oblique muscles was significantly greater in boys, while girls had a significantly greater incidence of late-onset refractive errors.
CONCLUSION: Botulinum toxin is an effective treatment modality for the management of infantile esotropia in infants and children, producing binocular alignment of the visual axes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9366672     DOI: 10.1001/archopht.1997.01100160581010

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

1.  Risk factors associated with poor outcome after medial rectus resection for recurrent intermittent exotropia.

Authors:  Jihei Sara Lee; Jinu Han; Sueng-Han Han
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-19       Impact factor: 3.117

2.  Early retreatment of infantile esotropia: comparison of reoperation and botulinum toxin.

Authors:  J Tejedor; J M Rodríguez
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

3.  Botulinum toxin injections combined with or without sodium hyaluronate in the absence of electromyography for the treatment of infantile esotropia: a pilot study.

Authors:  J Chen; D Deng; H Zhong; X Lin; Y Kang; H Wu; J Yan; G Mai
Journal:  Eye (Lond)       Date:  2012-12-14       Impact factor: 3.775

4.  Long-Term Effects of Botulinum Toxin in Large-Angle Infantile Esotropia.

Authors:  Flavio Gioele Gallo; Carmen Plaitano; Paolo Esposito Veneruso; Adriano Magli
Journal:  Clin Ophthalmol       Date:  2020-10-19

5.  Rates of Reoperation and Abnormal Binocularity Following Strabismus Surgery in Children.

Authors:  Christopher T Leffler; Kamyar Vaziri; Stephen G Schwartz; Kara M Cavuoto; Craig A McKeown; Krishna S Kishor; Adam C Janot
Journal:  Am J Ophthalmol       Date:  2015-11-05       Impact factor: 5.258

Review 6.  The role of drug treatment in children with strabismus and amblyopia.

Authors:  K I Chatzistefanou; M D Mills
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.930

7.  Comparison of botulinum toxin with surgery for the treatment of acute acquired comitant esotropia and its clinical characteristics.

Authors:  Li-Juan Lang; Yu Zhu; Zhi-Gang Li; Guang-Ying Zheng; Hai-Ying Peng; Jun-Bo Rong; Li-Min Xu
Journal:  Sci Rep       Date:  2019-09-25       Impact factor: 4.379

8.  Short-term outcome of botulinum neurotoxin A injection with or without sodium hyaluronate in the treatment of infantile esotropia-a prospective interventional study.

Authors:  Nitika Pandey; Siddharth Agrawal; Rajat M Srivastava; Vinita Singh
Journal:  Indian J Ophthalmol       Date:  2020-08       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.